10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension-Reference-Cited by-同舟云学术

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

Published:2017-07 Issue:7 Volume:5 Page:513-523
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Bone Henry G,Wagman Rachel B,Brandi Maria L,Brown Jacques P,Chapurlat Roland,Cummings Steven R,Czerwiński Edward,Fahrleitner-Pammer Astrid,Kendler David L,Lippuner Kurt,Reginster Jean-Yves,Roux Christian,Malouf Jorge,Bradley Michelle N,Daizadeh Nadia S,Wang Andrea,Dakin Paula,Pannacciulli Nicola,Dempster David W,Papapoulos Socrates

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference38 articles.

1. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis;Am J Med,1993

2. Bone health and osteoporosis: a report of the Surgeon General,2004

3. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases;Hofbauer;JAMA,2004

4. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women;Bekker;J Bone Miner Res,2004

5. Denosumab in postmenopausal women with low bone mineral density;McClung;N Engl J Med,2006

Cited by 691 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The use of denosumab in osteoporosis – an update on efficacy and drug safety;Expert Opinion on Drug Safety;2024-09-11

2. Eupatilin suppresses osteoclastogenesis and periodontal bone loss by inhibiting the MAPKs/Siglec-15 pathway;International Immunopharmacology;2024-09

3. A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab;Frontiers in Pharmacology;2024-08-30

4. Mouse model of uncoupled bone remodeling upon discontinuation of anti-RANKL antibody therapy;2024-08-27

5. Update on Atypical Femoral Fractures;Journal of Bone and Joint Surgery;2024-08-22